Cargando…

Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis

BACKGROUND: Several pharmaceutical treatments for chronic pain caused by osteoarthritis (OA) and chronic low back pain (CLBP) are available or currently under development, each associated with different adverse events (AEs) and efficacy profiles. It is therefore important to understand what trade‐of...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, David A., Boeri, Marco, Abraham, Lucy, Atkinson, Jo, Bushmakin, Andrew G., Cappelleri, Joseph C., Hauber, Brett, Klein, Kathleen, Russo, Leo, Viktrup, Lars, Turk, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303786/
https://www.ncbi.nlm.nih.gov/pubmed/34854164
http://dx.doi.org/10.1002/ejp.1892
_version_ 1784751953246420992
author Walsh, David A.
Boeri, Marco
Abraham, Lucy
Atkinson, Jo
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Hauber, Brett
Klein, Kathleen
Russo, Leo
Viktrup, Lars
Turk, Dennis
author_facet Walsh, David A.
Boeri, Marco
Abraham, Lucy
Atkinson, Jo
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Hauber, Brett
Klein, Kathleen
Russo, Leo
Viktrup, Lars
Turk, Dennis
author_sort Walsh, David A.
collection PubMed
description BACKGROUND: Several pharmaceutical treatments for chronic pain caused by osteoarthritis (OA) and chronic low back pain (CLBP) are available or currently under development, each associated with different adverse events (AEs) and efficacy profiles. It is therefore important to understand what trade‐offs patients are willing to make when choosing between treatments. METHODS: A discrete‐choice experiment (DCE) was conducted with 437 adults with chronic pain caused by OA and/or CLBP. Respondents were presented with a series of scenarios and asked to choose between pairs of hypothetical treatments, each defined by six attributes: level of symptom control; risks of heart attack, rapidly progressive osteoarthritis and dependency; frequency and mode of administration and cost. Attributes were based on known profiles of oral nonsteroidal anti‐inflammatory drugs, opioids and injected nerve growth factor inhibitors, the last of which were under clinical development at the time of the study. Data were analysed using a latent class (LC) model to explore preference heterogeneity. RESULTS: Overall, respondents considered improving symptom control and reducing risk of physical dependency to be the most important attributes. The LC analysis identified four participant classes: an ‘efficacy‐focused’ class (33.7%), a ‘cost‐averse’ class (29.4%), a ‘physical‐dependence–averse’ class (19.6%) and a ‘needle‐averse’ class (17.3%). Subgroup membership was incompletely predicted by participant age and their responses to comprehension questions. CONCLUSIONS: Preference heterogeneity across respondents indicates a need for a personalized approach to offering treatment options. Symptom improvement, cost, physical dependence and route of administration might be important to different patients. SIGNIFICANCE: Multiple treatment options that differ substantially in terms of efficacy and adverse events are available for the management of chronic pain. With a growing emphasis on a patient‐centred care model that incorporates patients’ priorities and values into treatment decisions, there is a need to understand how individuals with chronic musculoskeletal pain balance the benefits and risks of treatment and how treatment priorities vary among individuals. This study was designed to identify patient preferences for different characteristics of treatments for the management of chronic pain and to investigate how preferences differ among respondents.
format Online
Article
Text
id pubmed-9303786
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93037862022-07-28 Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis Walsh, David A. Boeri, Marco Abraham, Lucy Atkinson, Jo Bushmakin, Andrew G. Cappelleri, Joseph C. Hauber, Brett Klein, Kathleen Russo, Leo Viktrup, Lars Turk, Dennis Eur J Pain Original Articles BACKGROUND: Several pharmaceutical treatments for chronic pain caused by osteoarthritis (OA) and chronic low back pain (CLBP) are available or currently under development, each associated with different adverse events (AEs) and efficacy profiles. It is therefore important to understand what trade‐offs patients are willing to make when choosing between treatments. METHODS: A discrete‐choice experiment (DCE) was conducted with 437 adults with chronic pain caused by OA and/or CLBP. Respondents were presented with a series of scenarios and asked to choose between pairs of hypothetical treatments, each defined by six attributes: level of symptom control; risks of heart attack, rapidly progressive osteoarthritis and dependency; frequency and mode of administration and cost. Attributes were based on known profiles of oral nonsteroidal anti‐inflammatory drugs, opioids and injected nerve growth factor inhibitors, the last of which were under clinical development at the time of the study. Data were analysed using a latent class (LC) model to explore preference heterogeneity. RESULTS: Overall, respondents considered improving symptom control and reducing risk of physical dependency to be the most important attributes. The LC analysis identified four participant classes: an ‘efficacy‐focused’ class (33.7%), a ‘cost‐averse’ class (29.4%), a ‘physical‐dependence–averse’ class (19.6%) and a ‘needle‐averse’ class (17.3%). Subgroup membership was incompletely predicted by participant age and their responses to comprehension questions. CONCLUSIONS: Preference heterogeneity across respondents indicates a need for a personalized approach to offering treatment options. Symptom improvement, cost, physical dependence and route of administration might be important to different patients. SIGNIFICANCE: Multiple treatment options that differ substantially in terms of efficacy and adverse events are available for the management of chronic pain. With a growing emphasis on a patient‐centred care model that incorporates patients’ priorities and values into treatment decisions, there is a need to understand how individuals with chronic musculoskeletal pain balance the benefits and risks of treatment and how treatment priorities vary among individuals. This study was designed to identify patient preferences for different characteristics of treatments for the management of chronic pain and to investigate how preferences differ among respondents. John Wiley and Sons Inc. 2022-01-08 2022-03 /pmc/articles/PMC9303786/ /pubmed/34854164 http://dx.doi.org/10.1002/ejp.1892 Text en © 2021 Pfizer Inc. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation ‐ EFIC® https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Walsh, David A.
Boeri, Marco
Abraham, Lucy
Atkinson, Jo
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Hauber, Brett
Klein, Kathleen
Russo, Leo
Viktrup, Lars
Turk, Dennis
Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
title Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
title_full Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
title_fullStr Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
title_full_unstemmed Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
title_short Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
title_sort exploring patient preference heterogeneity for pharmacological treatments for chronic pain: a latent class analysis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303786/
https://www.ncbi.nlm.nih.gov/pubmed/34854164
http://dx.doi.org/10.1002/ejp.1892
work_keys_str_mv AT walshdavida exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT boerimarco exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT abrahamlucy exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT atkinsonjo exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT bushmakinandrewg exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT cappellerijosephc exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT hauberbrett exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT kleinkathleen exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT russoleo exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT viktruplars exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis
AT turkdennis exploringpatientpreferenceheterogeneityforpharmacologicaltreatmentsforchronicpainalatentclassanalysis